Trial Profile
Phase II study exploring reduction method of Lenvatinib for the patients with advanced hepatocellular carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Lenvatinib reduction study
- 02 May 2018 New trial record